Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need
| Autor: | Hongxing Pan, Yanfei Wu, Fengcai Zhu, Pengfei Jin, Jingxin Li |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Cancer Research 2019-20 coronavirus outbreak medicine.medical_specialty COVID-19 Vaccines Coronavirus disease 2019 (COVID-19) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lcsh:Medicine 03 medical and health sciences 0302 clinical medicine Pandemic Genetics Humans Medicine 030212 general & internal medicine Intensive care medicine Pandemics lcsh:QH301-705.5 Vaccines SARS-CoV-2 business.industry Surrogate endpoint lcsh:R COVID-19 030104 developmental biology Clinical Trials Phase III as Topic Immune correlates lcsh:Biology (General) Perspective Prevention control business Biomarkers |
| Zdroj: | Signal Transduction and Targeted Therapy, Vol 6, Iss 1, Pp 1-6 (2021) Signal Transduction and Targeted Therapy |
| ISSN: | 2059-3635 |
| Popis: | In response to the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic, over 200 vaccine candidates against coronavirus disease 2019 (COVID-2019) are under development and currently moving forward at an unparalleled speed. The availability of surrogate endpoints would help to avoid large-scale filed efficacy trials and facilitate the approval of vaccine candidates, which is crucial to control COVID-19 pandemic. Several phase 3 efficacy trials of COVID-19 vaccine candidates are under way, which provide opportunities for the determination of COVID-19 correlates of protection. In this paper, we review current knowledge for existence of COVID-19 correlates of protection, methods for assessment of immune correlates of protection and issues related to COVID-19 correlates of protection. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|